@article{c28370bfbaac47c99802f0043499f889,
title = "Risk of severe hypoglycemia in type 1 diabetes over 30 years of follow-up in the dcct/edic study",
abstract = "OBJECTIVE During theDiabetes Control and Complications Trial (DCCT), intensive diabetes therapy achieving a mean HbA1c of ?7% was associated with a threefold increase in the rate of severe hypoglycemia (defined as requiring assistance) compared with conventional diabetes therapywith ameanHbA1c of9%(61.2 vs. 18.7 per 100 patient-years). After?30 years of follow-up,we investigated the rates of severe hypoglycemia in the DCCT/Epidemiology of Diabetes Inverventions and Complications (EDIC) cohort. RESEARCH DESIGN AND METHODS Rates of severe hypoglycemia were reported quarterly during DCCT and annually during EDIC (i.e., patient recall of episodes in the preceding 3 months). Risk factors influencing the rate of severe hypoglycemia over time were investigated. RESULTS One-half of the DCCT/EDIC cohort reported episodes of severe hypoglycemia. During EDIC, rates of severe hypoglycemia fell in the former DCCT intensive treatment group but rose in the former conventional treatment group, resulting in similar rates (36.6 vs. 40.8 episodes per 100 patient-years, respectively) with a relative risk of 1.12 (95% CI 0.91-1.37). A preceding episode of severe hypoglycemia was the most powerful predictor of subsequent episodes. Entry into the DCCT study as an adolescent was associated with an increased risk of severe hypoglycemia,whereas insulin pump use was associated with a lower risk. Severe hypoglycemia rates increased with lower HbA1c similarly among participants in both treatment groups. CONCLUSIONS Rates of severe hypoglycemia have equilibrated over time between the two DCCT/ EDIC treatment groups in association with advancing duration of diabetes and similar HbA1c levels. Severe hypoglycemia persists and remains a challenge for patientswith type 1 diabetes across their life span.",
author = "Gubitosi-Klug, {Rose A.} and Braffett, {Barbara H.} and White, {Neil H.} and Sherwin, {Robert S.} and Service, {F. John} and Lachin, {John M.} and Tamborlane, {William V.}",
note = "Funding Information: Acknowledgments.DavidM.Nathanisacknowl- edged as the editor for DCCT/EDIC publications. Funding.The DCCT/EDIC hasbeensupportedby cooperative agreement grants (1982–1993, 2012–2017) and contracts (1982–2012) with the Division of Diabetes, Endocrinology, and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney Diseases (current grant numbers U01-DK-094176 and U01-DK-094157) and through support by the National Eye Institute, the National Institute of Neurological Disorders and Stroke, the General Clinical Research Centers Program (1993–2007), and the Clinical Translational Science Center Program (2006–present), Bethesda, MD. Duality of Interest. Industry contributors played no role in the DCCT/EDIC study but have provided free or discounted supplies or equipment to support participants{\textquoteright} adherence to the study: Abbott Diabetes Care (Alameda, CA), Animas (Westches-ter, PA), Bayer Diabetes Care (North America Headquarters, Tarrytown, NY), Becton Dickinson (Franklin Lakes, NJ), Eli Lilly (Indianapolis, IN), Extend Nutrition (St. Louis, MO), Insulet Corporation (Bedford, MA), Lifescan (Milpitas, CA), Medtronic Diabetes (Minneapolis, MN), Nipro Home Diagnostics (Ft. Lauderdale, FL), Nova Diabetes Care (Billerica, MA), Omron (Shelton, CT), Perrigo Diabetes Care (Allegan, MI), Roche Diabetes Care (Indianapolis, IN), and Sanofi (Bridgewater NJ). No other potential conflicts of interest relevant to this article were reported. Author Contributions. R.A.G.-K. and J.M.L. obtained funding for the study and wrote the manuscript. B.H.B. and J.M.L. directed and conducted the statistical analyses. R.A.G.-K., B.H.B., N.H.W., F.J.S., J.M.L., and W.V.T. interpreted the data, wrote sections of the manuscript, and reviewed and edited the manuscript. R.S.S. contributed to interpreting the results and reviewing the manuscript. B.H.B. and J.M.L. contributed to the analysis plan specifications for the manuscript. B.H.B. is the guarantor of this workand,assuch,hadfullaccesstoallthedatain the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.",
year = "2017",
month = aug,
day = "1",
doi = "10.2337/dc16-2723",
language = "English",
volume = "40",
pages = "1010--1016",
journal = "Diabetes care",
issn = "0149-5992",
number = "8",
}